IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NORTH CAROLINA Western Division

No. 5:12-CV-00077

)	
)	
)	
)	
)	COMPLAINT FOR PATENT
)	INFRINGEMENT
)	
)	
)	
)	(JURY TRIAL DEMANDED)
)	
)	

Plaintiff Precision BioSciences, Inc. brings this action for patent infringement against defendants Cellectis SA, Cellectis bioresearch and Cellectis bioresearch Inc., alleging as follows, on personal knowledge as to its own activities and on information and belief as to all other matters:

PARTIES

- 1. Plaintiff Precision BioSciences, Inc. ("Precision") is a Delaware corporation having a principal place of business at 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, North Carolina 27701.
- 2. Defendant Cellectis SA ("Cellectis") is a corporation organized under the laws of France having a principal place of business at 8 Rue de la Croix Jarry, 75013 Paris, France.
- 3. Defendant Cellectis bioresearch ("Cellectis bioresearch") is a corporation organized under the laws of France having a principal place of business at 8 Rue de la Croix Jarry 75013, France. Cellectis bioresearch is a subsidiary of Cellectis established in 2008.

4. Defendant Cellectis bioresearch Inc. ("Cellectis bioresearch USA") is a Delaware corporation having a principal place of business at One Broadway, Cambridge Massachusetts 02142. Cellectis bioresearch USA is a subsidiary of Cellectis bioresearch established in 2010 and is responsible for the US-wide promotion of Cellectis bioresearch products and services.

JURISDICTION AND VENUE

- 5. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and 1338(a) because this action arises under the patent laws of the United States, 35 U.S.C. § 101, et seq.
- 6. This Court has personal jurisdiction over Cellectis, Cellectis bioresearch and Cellectis bioresearch USA because, *inter alia*, they regularly conduct business in North Carolina and in this judicial district, directly and through their agents, and they have committed acts of infringement in North Carolina and in this judicial district.
- 7. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391(b), 1391(d) and 1400(b).

INFRINGEMENT OF U.S. PATENT NO. 8,119,381

- 8. United States Patent No. 8,119,381 (the "'381 patent"), entitled "Rationally Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity," was duly and legally issued by the United States Patent and Trademark Office on February 21, 2012.
- 9. Precision is the exclusive licensee of the '381 patent and owner of all substantial rights therein and thereto, including but not limited to the right to institute and to maintain proceedings in its own name for infringement of the '381 patent by others.
- 10. Cellectis, Cellectis bioresearch and/or Cellectis bioresearch USA have infringed and, upon information and belief, will continue, subsequent to the filing of this action, to infringe one or more claims of the '381 patent in violation of 35 U.S.C. § 271 by making, using, offering

for sale, selling and importing into the United States one or more products, including but not limited to meganucleases targeting the HIV1 genome and meganucleases targeting the GS gene in Chinese Hamster Ovary cells, and/or by contributing to and inducing others to make, use, offer for sale, sell and import into the United States one or more products, including but not limited to meganucleases targeting the HIV1 genome and meganucleases targeting the GS gene in Chinese Hamster Ovary cells.

- 11. As a result of the infringement of the '381 patent by Cellectis, Cellectis bioresearch and/or Cellectis bioresearch USA, Precision has suffered and continues to suffer injury to its business and property in an amount to be determined as damages.
- 12. Unless an injunction is issued enjoining Cellectis, Cellectis bioresearch and Cellectis bioresearch USA, and their respective officers, agents, servants, employees and attorneys, and all those persons and entities in active concert and participation with them, from infringing the '381 patent, Precision will be irreparably harmed.

PRAYER FOR RELIEF

WHEREFORE, Precision respectfully requests entry of a judgment that includes:

- A. A finding that Cellectis, Cellectis bioresearch and Cellectis bioresearch USA have infringed the '381 patent;
- B. A preliminary and permanent injunction enjoining Cellectis, Cellectis bioresearch and Cellectis bioresearch USA, and their respective officers, agents, servants, employees and attorneys, and all those persons and entities in active concert with them, from infringing the '381 patent;
- C. An award of damages in favor of Precision and against Cellectis, Cellectis bioresearch and Cellectis bioresearch USA, such damages being in an amount

sufficient to fully compensate Precision for infringement of the '381 patent by Cellectis, Cellectis bioresearch and Cellectis bioresearch USA, and an assessment of prejudgment and post-judgment interest;

- D. A finding by the Court that this is an exceptional case under 35 U.S.C. § 285 and an award to Precision of its costs, expenses and attorneys' fees in this action; and
- E. Such other and further relief as the Court deems just and proper.

DEMAND FOR JURY TRIAL

Precision hereby demands trial by jury as to all issues triable by jury as of right.

This the 21st day of February, 2012.

/s/ Robert J. Morris

Robert J. Morris N.C. State Bar No. 15981 jmorris@smithlaw.com SMITH ANDERSON BLOUNT DORSETT MITCHELL & JERNIGAN, LLP Wells Fargo Capitol Center Post Office Box 2611 Raleigh, North Carolina 27602-2611 Telephone: (919) 821-6800

Facsimile: (919) 821-6800

Attorneys for Plaintiff Precision BioSciences, Inc.

OF COUNSEL:

E. Anthony Figg
efigg@rothwellfigg.com
Sharon E. Crane, Ph.D.
scrane@rothwellfigg.com
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
607 14th Street, N.W.
Suite 800
Washington, DC 20005
Telephone: (202) 783-6040

Telephone: (202) 783-6040 Facsimile: (202) 783-6031